00:10cari fred carissimi di recente durante alcuni controlli i medici mi hanno trovato un nodulo
00:19circoscritto al polmone è stato individuato in una fase molto iniziale e ben localizzato
00:27i medici ritengono opportuno intervenire e allora seguendo i loro consigli ho deciso di operarmi per toglierlo
00:37l'intervento è già programmata nei prossimi giorni vi ringrazio per la vostra vicinanza spirituale e mi affido alla vostra
00:48preghiera
00:56grazie buona domenica
01:27buona domenica
01:31so lung cancer is a one of the most well-known principal solid tumors for human and we know
01:39that we have generally 2.5 new diagnoses ever here worldwide lung cancer today is a not a unique
01:47disease but we know that according on the pathology feature also biology understanding we can split
01:55measure lung cancer in different kind of subgroups the major is adenocarcinoma lung cancer that more
02:04or less account for 40 percent of all the new case
02:18in the discussion with the patient is important to identify the correct stage but the diagnosi of
02:24adenocarcinoma today among all the diagnoses lung cancer is a mostly the the best diagnoses because
02:31we have the opportunity through the molecular profile the immune mediating profile to have a
02:37very big scenario treatment strategy to deliver in the clinical setting and for adenocarcinoma our
02:45treatment strategy and the progress in this treatment strategy are today a reality to have a long-term
02:51effective benefit
03:11and you can discover lung cancer generally having a CT scan identify a small
03:18lesion in the lungs or after the development of some new symptoms like a cough dyspnea of chest pain
03:27of course this is something of an initial workflow that move the doctors who ask to request new testing in
03:35particular CT scan that is the best diagnostic tools and methods to identify new lesions in the lungs
04:01the the stage of lung cancer are very very different we move from stage one to stage four and the
04:08difference is important stage one and stage two are different
04:12disease that generally localize in the lungs with the absent or small involvement than the lymph nodes
04:20for stage one and stage two generally we have a high potential of a cure through surgery plus or not
04:28the addiction of a therapeutic strategy for stage three we have a disease that generally spread to the lymph node
04:37and is confined in the lungs and here we have the opportunity to consider the
04:42combination strategy including surgery chemotherapy
04:45chemotherapy immunotherapy and also radiotherapy
04:49stage four is the stage that confirm that we the tumor spread outside of the lungs we have in the
04:57situation to have a metastasis
04:59sometimes in other organs like bone like a brain a lot adrenal gland in for stage four we have the
05:07opportunity to use different therapeutic strategy including chemo
05:12include the target agent immunotherapy sometimes also treatment for oligo disease
05:17but in this stage stage stage four the opportunity of cure very very limited and we dedicate our treatment to
05:24improve and to prolong the survival of our patients
05:36early diagnosis of course is the key for a cure
05:40and high rate of cure in particularly for stage one where the nodal is isolated in the lungs without any
05:48node involvement or for stage two where we can identify some lymph node involvement the opportunity to have a high
05:55cure rate is very very high achieved with the only surgery or the surgery followed by medical treatment
06:03is generally the use of
06:29the drugs as a chemo immunotherapy on target agent for patient with early
06:35stage are considered only to maximize the results of the surgery and to reduce
06:42the rate of the relapse and long-term relapse. For patient with advanced stage
06:47chemo, immuno or also other drugs like target agents are used to prolong the
06:55survival to maintain the disease under control.
07:30So more or less 15 years ago the opportunity to have a cure, uncovering a long-term benefit
07:36of patients with lung cancer was very very limited, less than 10%. Today we
07:41increase dramatically the opportunity to have a cure for patients with a radically
07:46resected disease stage 1 stage 2 and we have a high opportunity to have a long
07:52third benefit also in patients with the stage 4 lung cancer using the treatment
07:58strategy like chemotherapy, immunotherapy or target agent with a significant improvement
08:03in the 2, 3, 4 year survival rate, something that was imaginable in the 10 or 15 years ago.
08:12The first thing I would like to say is thanks, thanks for the support of your prayers.
08:19Thanks to God for His generosity. We all renew our trust in the kindness and the mercy of God.
08:35We know that for adenocarcinoma histology the molecular profiling that is able to be used to
08:41identify different kinds of gene alteration is able to drive us in the selection of the best treatment strategy.
08:48This was the major progress that of course moved us as oncologists as a doctor to identify the best treatment
08:56strategy.
08:58Today we have more or less 10 different target agents that we can use according to different kinds of gene
09:05alteration.
09:05we have many opportunities to use immunotherapy alone or in combination with chemotherapy.
09:12But importantly all of this kind of opportunity and the treatment strategy should be delivered
09:18according to the pathology, according to the biology, to the right place and to the right patients.
09:58And the Sapiens that not only need the power of a keeping the divine waitии even as if you are
10:00willing to be here.
10:00So we will see you quickly from the investigation at any complaint based on the validation SO.
10:00Today we continue to follow our YouTube videos, we believe now on our list.
10:00If something is fixed then child care, listeners have to go and have to take root fiveades,
10:03You
